

Chapter 102

Neurobiology of the Skin

Martin Steinhoff & Thomas A. Luger

REFERENCES

1. Roosterman D et al: Neuronal control of skin function: The skin as a neuroimmunoendocrine organ. *Physiol Rev* **86**:1309-1379, 2006
2. Peters EM et al: Neuropeptide control mechanisms in cutaneous biology: Physiological and clinical significance. *J Invest Dermatol* **126**:1937-1947, 2006
3. Scholzen TE, Luger TA: Neutral endopeptidase and angiotensin-converting enzyme—Key enzymes terminating the action of neuroendocrine mediators. *Exp Dermatol* **13**(Suppl.) **4**:22-26, 2004
4. Zylka MJ, Rice FL, Anderson DJ: Topographically distinct epidermal nociceptive circuits revealed by axonal tracers targeted to Mrgprd. *Neuron* **45**:17-25, 2005
5. Charkoudian N: Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans. *J Appl Physiol*
6. Chapman BP, Moynihan J: The brain-skin connection: Role of psychosocial factors and neuropeptides in psoriasis. *Expert Rev Clin Immunol* **5**:623-627, 2009
7. Reich A, Wojcik-Maciejewicz A, Slominski AT: Stress and the skin. *G Ital Dermatol Venereol* **145**:213-219, 2010
8. Theoharides TC et al: IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. *Proc Natl Acad Sci U S A* **107**:4448-4453, 2010
9. Buddenkotte J, Steinhoff M: Pathophysiology and therapy of pruritus in allergic and atopic diseases. *Allergy* **65**:805-821, 2010
10. Ganceviciene R et al: The role of neuropeptides in the multifactorial pathogenesis of acne vulgaris. *Dermatoendocrinol* **1**:170-176, 2009
11. Pradhan L et al: Gene expression of pro-inflammatory cytokines and neuropeptides in diabetic wound healing. *J Surg Res* **167**(2):336-342, 2009
12. Bodo E et al: Thyroid-stimulating hormone, a novel, locally produced modulator of human epidermal functions, is regulated by thyrotropin-releasing hormone and thyroid hormones. *Endocrinology* **151**:1633-1642, 2010
13. Ito N et al: Corticotropin-releasing hormone stimulates the in situ generation of mast cells from precursors in the human hair follicle mesenchyme. *J Invest Dermatol* **130**:995-1004, 2010
14. Poeggeler B et al: Thyrotropin powers human mitochondria. *FASEB J* **24**:1525-1531, 2010
15. Sun YG, Chen ZF: A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. *Nature* **448**:700-703, 2007
16. Sun YG et al: Cellular basis of itch sensation. *Science* **325**:1531-1534, 2009
17. Winkelmann RK: Cutaneous sensory nerves. *Semin Dermatol* **7**:236-268, 1988
18. Munger BL, Ide C: The structure and function of cutaneous sensory receptors. *Arch Histol Cytol* **51**:1-34, 1988
19. Breathnach AS: Electron microscopy of cutaneous nerves and receptors. *J Invest Dermatol* **69**:8-26, 1977
20. Tschachler E et al: Sheet preparations expose the dermal nerve plexus of human skin and render the dermal nerve end organ accessible to extensive analysis. *J Invest Dermatol* **122**:177-182, 2004
21. Kelly EJ et al: Nerve fibre and sensory end organ density in the epidermis and papillary dermis of the human hand. *Br J Plast Surg* **58**:774-779, 2005
22. Yamada N, Kashima Y, Inoue T: Scanning electron microscopy of the basal surface of the epidermis of human digits. *Acta Anat (Basel)* **155**:242-248, 1996
23. Alvarez FJ, Fyffe RE: Nociceptors for the 21st century. *Curr Rev Pain* **4**:451-458, 2000
24. Lawson SN: Phenotype and function of somatic primary afferent nociceptive neurones with C-, Aδ- or Aα/β-fibres. *Exp Physiol* **87**:239-244, 2002
25. Schmidt R et al: Novel classes of responsive and unresponsive C nociceptors in human skin. *J Neurosci* **15**:333-341, 1995
26. Basbaum AI et al: Cellular and molecular mechanisms of pain. *Cell* **139**:267-284, 2009

27. Zimmermann K et al: Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures. *Nature* **447**:855-858, 2007
28. Caterina MJ et al: The capsaicin receptor: A heat-activated ion channel in the pain pathway [see comments]. *Nature* **389**:816-824, 1997
29. Slominski A, Wortsman J: Neuroendocrinology of the skin. *Endocr Rev* **21**:457-487, 2000
30. Slominski A et al: Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. *Physiol Rev* **80**:979-1020, 2000
31. Brain SD, Moore PK, eds: *Pain and Neurogenic Inflammation*. Basel, Birkhäuser Verlag, 1999
32. Vetrugno R et al: Sympathetic skin response: Basic mechanisms and clinical applications. *Clin Auton Res* **13**:256-270, 2003
33. Tainio H, Vaalasti A, Rechartd L: The distribution of substance P-, CGRP-, galanin- and ANP-like immunoreactive nerves in human sweat glands. *Histochem J* **19**:375-380, 1987
34. Bjorklund H et al: Sensory and autonomic innervation of non-hairy and hairy human skin. An immunohistochemical study. *Cell Tissue Res* **243**:51-57, 1986
35. Polak JM, Bloom SR: Regulatory peptides—The distribution of two newly discovered peptides: PHI and NPY. *Peptides* **5**(Suppl 1.):79-89, 1984
36. Rao MS, Landis SC: Cell interactions that determine sympathetic neuron transmitter phenotype and the neurokinins that mediate them. *J Neurobiol* **24**:215-232, 1993
37. Habecker BA et al: Target regulation of VIP expression in sympathetic neurons. *Ann N Y Acad Sci* **814**:198-208, 1997
38. Izumi H: Nervous control of blood flow in the orofacial region. *Pharmacol Ther* **81**:141-161, 1999
39. Kaji A et al: Parasympathetic innervation of cutaneous blood vessels by vasoactive intestinal polypeptide-immunoreactive and acetylcholinesterase-positive nerves: Histochemical and experimental study on rat lower lip. *Neuroscience* **25**:353-362, 1988
40. Advenier C, Devillier P: Neurokinins and the skin. *Allerg Immunol (Paris)* **25**:280-282, 285, 1993
41. Brain SD, Williams TJ: Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. *Br J Pharmacol* **86**:855-860, 1985
42. Wallengren J et al: Innervation of the skin of the forearm in diabetic patients: Relation to nerve function. *Acta Derm Venereol* **75**:37-42, 1995
43. Hamberger B, Norberg KA: Histochemical demonstration of catecholamines in fresh frozen sections. *J Histochem Cytochem* **12**:48-49, 1964
44. Bennett LA et al: Evidence for a role for vasoactive intestinal peptide in active vasodilatation in the cutaneous vasculature of humans. *J Physiol* **552**:223-232, 2003
45. Burnstock G: Purinergic cotransmission. *Brain Res Bull* **50**:355-357, 1999
46. Stephens DP et al: Neuropeptide Y antagonism reduces reflex cutaneous vasoconstriction in humans. *Am J Physiol Heart Circ Physiol* **287**:H1404-H1409, 2004
47. Groetzner P, Weidner C: The human vasodilator axon reflex—An exclusively peripheral phenomenon? *Pain* **149**:71-75
48. Steinhoff M et al: Neurophysiological, neuro-immunological, and neuroendocrine basis of pruritus. *J Invest Dermatol* **126**:1705-1718, 2006
49. Bohm M et al: Melanocortin receptor ligands: New horizons for skin biology and clinical dermatology. *J Invest Dermatol* **126**:1966-1975, 2006
50. Reilly DM et al: The epidermal nerve fibre network: Characterization of nerve fibres in human skin by confocal microscopy and assessment of racial variations. *Br J Dermatol* **137**:163-170, 1997
51. Misery L: Skin, immunity and the nervous system. *Br J Dermatol* **137**:843-850, 1997
52. Steinhoff M et al: Modern aspects of cutaneous neurogenic inflammation. *Arch Dermatol* **139**:1479-1488, 2003
53. Namazi MR: Paradoxical exacerbation of psoriasis in AIDS: Proposed explanations including the potential roles of substance P and gram-negative bacteria. *Autoimmunity* **37**:67-71, 2004
54. Nakano Y: Stress-induced modulation of skin immune function: Two types of antigen-presenting cells in the epidermis are differentially regulated by chronic stress. *Br J Dermatol* **151**:50-64, 2004
55. O'Connor TM et al: The role of substance P in inflammatory disease. *J Cell Physiol* **201**:167-180, 2004
56. Orsal AS et al: The progesterone derivative hydrocortisone down-regulates neurokinin 1 receptor expression on lymphocytes, induces a Th2 skew and exerts hypoalgesic effects in mice. *J Mol Med* **84**:159-167, 2006

57. Lighvani S et al: Substance P regulates natural killer cell interferon-gamma production and resistance to *Pseudomonas aeruginosa* infection. *Eur J Immunol* **35**:1567-1575, 2005
58. Brogden KA et al: The nervous system and innate immunity: The neuropeptide connection. *Nat Immunol* **6**:558-564, 2005
59. Ho WZ, Douglas SD: Substance P and neurokinin-1 receptor modulation of HIV. *J Neuroimmunol* **157**:48-55, 2004
60. Delgado AV, McManus AT, Chambers JP: Exogenous administration of Substance P enhances wound healing in a novel skin-injury model. *Exp Biol Med (Maywood)* **230**:271-280, 2005
61. Peters EM et al: Stress exposure modulates peptidergic innervation and degranulates mast cells in murine skin. *Brain Behav Immun* **19**:252-262, 2005
62. Svensson A et al: Neurokinin 1 receptor signaling affects the local innate immune defense against genital herpes virus infection. *J Immunol* **175**:6802-6811, 2005
63. Manske JM, Hanson SE: Substance-P-mediated immunomodulation of tumor growth in a murine model. *Neuroimmunomodulation* **12**:201-210, 2005
64. Marriott I: The role of tachykinins in central nervous system inflammatory responses. *Front Biosci* **9**:2153-2165, 2004
65. Paus R et al: Frontiers in pruritus research: Scratching the brain for more effective itch therapy. *J Clin Invest* **116**:1174-1186, 2006
66. van der Kleij HP et al: The tachykinin NK1 receptor is crucial for the development of non-atopic airway inflammation and hyperresponsiveness. *Eur J Pharmacol* **476**:249-255, 2003
67. Lai X et al: Effect of substance P released from peripheral nerve ending on endogenous expression of epidermal growth factor and its receptor in wound healing. *Chin J Traumatol* **5**:176-179, 2002
68. Burbach GJ et al: The neurosensory tachykinins substance P and neurokinin A directly induce keratinocyte nerve growth factor. *J Invest Dermatol* **117**:1075-1082, 2001
69. Viac J et al: Substance P and keratinocyte activation markers: An in vitro approach. *Arch Dermatol Res* **288**:85-90, 1996
70. Kahler CM et al: Stimulation of the chemotactic migration of human fibroblasts by substance P. *Eur J Pharmacol* **249**:281-286, 1993
71. Palframan RT et al: The effect of a tachykinin NK1 receptor antagonist, SR140333, on oedema formation induced in rat skin by venom from the *Phoneutria nigriventer* spider. *Br J Pharmacol* **118**:295-298, 1996
72. Scholzen TE et al: Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage. *FASEB J* **18**:1007-1009, 2004
73. Stander S et al: Targeting the neurokinin receptor 1 with aprepitant: A novel antipruritic strategy. *PLoS One* **5**:e10968, 2010
74. Vincenzi B et al: Aprepitant against pruritus in patients with solid tumours. *Support Care Cancer*
75. Duval A, Dubertret L: Aprepitant as an antipruritic agent? *N Engl J Med* **361**:1415-1416, 2009
76. Schulze E et al: Immunohistochemical detection of human skin nerve fibers. *Acta Histochem* **99**:301-309, 1997
77. Hartschuh W, Weihe E, Reinecke M: Peptidergic (neurotensin, VIP, substance P) nerve fibres in the skin. Immunohistochemical evidence of an involvement of neuropeptides in nociception, pruritus and inflammation. *Br J Dermatol* **109**(Suppl. 25):14-17, 1983
78. Naukkarinen A et al: Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions. *Arch Dermatol Res* **285**:341-346, 1993
79. Harvima IT et al: Association of cutaneous mast cells and sensory nerves with psychic stress in psoriasis. *Psychother Psychosom* **60**:168-176, 1993
80. Groneberg DA et al: Down-regulation of vasoactive intestinal polypeptide receptor expression in atopic dermatitis. *J Allergy Clin Immunol* **111**:1099-1105, 2003
81. Eedy DJ et al: Vasoactive intestinal peptide (VIP) and peptide histidine methionine (PHM) in human eccrine sweat glands: Demonstration of innervation, specific binding sites and presence in secretions. *Br J Dermatol* **123**:65-76, 1990
82. Sato K, Sato F: Effect of VIP on sweat secretion and cAMP accumulation in isolated simian eccrine glands. *Am J Physiol* **253**:R935-R941, 1987
83. Eedy DJ et al: The regional distribution of neuropeptides in human skin as assessed by radioimmunoassay and high-performance liquid chromatography. *Clin Exp Dermatol* **19**:463-472, 1994

84. Kellogg DL et al: VIP/PACAP receptor mediation of cutaneous active vasodilation during heat stress in humans. *J Appl Physiol* **109**:95-100, 2010
85. Schytz HW et al: Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP. *J Headache Pain* **11**:309—316, 2010
86. Anand P et al: A VIP-containing system concentrated in the lumbosacral region of human spinal cord. *Nature* **305**:143-145, 1983
87. Warren JB et al: Opposing roles of cyclic AMP in the vascular control of edema formation. *Faseb J* **7**:1394-1400, 1993
88. Kakurai M et al: Vasoactive intestinal peptide and inflammatory cytokines enhance vascular endothelial growth factor production from epidermal keratinocytes. *Br J Dermatol* **161**:1232-1238, 2009
89. Veljkovic V, Metlas R: Application of VIP/NTM-reactive natural antibodies in therapy of HIV disease. *Int Rev Immunol* **23**:437-445, 2004
90. Delgado M et al: VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. *J Leukoc Biol* **75**:1122-1130, 2004
91. Gonzalez-Rey E, Delgado M: Role of vasoactive intestinal peptide in inflammation and autoimmunity. *Curr Opin Investig Drugs* **6**:1116-1123, 2005
92. Delgado M et al: Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. *J Leukoc Biol* **78**:1327-1338, 2005
93. Delgado M et al: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. *J Immunol* **162**:1200-1205, 1999
94. Delgado M et al: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: In vitro and in vivo studies. *J Immunol* **162**:2358-2367, 1999
95. Gutierrez-Canas I et al: VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. *Rheumatology* **45**:527-532, 2006
96. Dun NJ et al: Pituitary adenylate cyclase activating polypeptide immunoreactivity in the rat spinal cord and medulla: Implication of sensory and autonomic functions. *Neuroscience* **73**:677-686, 1996
97. Moller K et al: Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: Immunocytochemical and immunochemical evidence. *Neuroscience* **57**:725-732, 1993
98. Armstrong BD et al: Restoration of axotomy-induced PACAP gene induction in SCID mice with CD4+ T-lymphocytes. *Neuroreport* **15**:2647-2650, 2004
99. Steinhoff M et al: Identification of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in human skin: Expression of PACAP-38 is increased in patients with psoriasis. *Regul Pept* **80**:49-55, 1999
100. Odum L et al: Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. *Inflamm Res* **47**:488-492, 1998
101. Pincelli C et al: Substance P is diminished and vasoactive intestinal peptide is augmented in psoriatic lesions and these peptides exert disparate effects on the proliferation of cultured human keratinocytes. *J Invest Dermatol* **98**:421-427, 1992
102. Zhang YZ et al: Pituitary adenylate cyclase activating peptide produces a marked and long-lasting depression of a C-fibre-evoked flexion reflex. *Neuroscience* **57**:733-737, 1993
103. Jongasma H et al: Markedly reduced chronic nociceptive response in mice lacking the PAC1 receptor. *Neuroreport* **12**:2215-2219, 2001
104. Cardell LO et al: PACAP-induced plasma extravasation in rat skin. *Regul Pept* **71**:67-71, 1997
105. Schmidt-Choudhury A et al: Mast cells contribute to PACAP-induced dermal oedema in mice. *Regul Pept* **82**:65-69, 1999
106. Fizanne L et al: Evidence for the involvement of VPAC1 and VPAC2 receptors in pressure-induced vasodilatation in rodents. *J Physiol* **554**:519-528, 2004
107. Seeliger S et al: Pituitary Adenylate Cyclase Activating Polypeptide: An Important Vascular Regulator in Human Skin in vivo. *Am J Pathol* **177**:2563-2575, 2010
108. Gibbins IL, Wattchow D, Coventry B: Two immunohistochemically identified populations of calcitonin gene-related peptide (CGRP)-immunoreactive axons in human skin. *Brain Res* **414**:143-148, 1987
109. Brain SD, Grant AD: Vascular actions of calcitonin gene-related peptide and adrenomedullin. *Physiol Rev* **84**:903-934, 2004
110. Botchkarev VA et al: A simple immunofluorescence technique for simultaneous visualization of mast cells and nerve fibers reveals selectivity and hair cycle-dependent changes in mast cell-nerve fiber contacts in murine skin. *Arch Dermatol Res* **289**:292-302, 1997

111. Fantini F et al: Cutaneous innervation in chronic renal failure patients. An immunohistochemical study. *Acta Derm Venereol* **72**:102-105, 1992
112. Hara M et al: Innervation of melanocytes in human skin. *J Exp Med* **184**:1385-1395, 1996
113. Asahina A et al: Specific induction of cAMP in Langerhans cells by calcitonin gene-related peptide: Relevance to functional effects. *Proc Natl Acad Sci U S A* **92**:8323-8327, 1995
114. Hosoi J et al: Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. *Nature* **363**:159-163, 1993
115. Averbeck B et al: Inflammatory mediators do not stimulate CGRP release if prostaglandin synthesis is blocked by S(+)-flurbiprofen in isolated rat skin. *Inflamm Res* **52**:519-523, 2003
116. Kresse A, Jacobowitz DM, Skofitsch G: Distribution of calcitonin gene-related peptide in the central nervous system of the rat by immunocytochemistry and in situ hybridization histochemistry. *Ann NY Acad Sci* **657**:455-457, 1992
117. Wallengren J, Ekman R, Sundler F: Occurrence and distribution of neuropeptides in the human skin. An immunocytochemical and immunohistochemical study on normal skin and blister fluid from inflamed skin. *Acta Derm Venereol* **67**:185-192, 1987
118. Tam C, Brain SD: The assessment of vasoactive properties of CGRP and adrenomedullin in the microvasculature: A study using in vivo and in vitro assays in the mouse. *J Mol Neurosci* **22**:117-124, 2004
119. Kiss M et al: Effects of the neuropeptides substance P, calcitonin gene-related peptide and alpha-melanocyte-stimulating hormone on the IL-8/IL-8 receptor system in a cultured human keratinocyte cell line and dermal fibroblasts. *Inflammation* **23**:557-567, 1999
120. Wimalawansa SJ: Calcitonin gene-related peptide and its receptors: Molecular genetics, physiology, pathophysiology, and therapeutic potentials. *Endocr Rev* **17**:533-585, 1996
121. Ichinose M, Sawada M: Enhancement of phagocytosis by calcitonin gene-related peptide (CGRP) in cultured mouse peritoneal macrophages. *Peptides* **17**:1405-1414, 1996
122. Sung CP et al: CGRP stimulates the adhesion of leukocytes to vascular endothelial cells. *Peptides* **13**:429-434, 1992
123. Scholzen TE et al: Calcitonin gene-related peptide (CGRP) activation of human dermal microvascular endothelial cell (HDMEC) transcription factors NF-kappa B and CREB. *J Invest. Dermatol.* **115**:534, 2000
124. Jansen-Olesen I, Mortensen A, Edvinsson L: Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase [see comments]. *Cephalalgia* **16**:310-316, 1996
125. Brain SD et al: Calcitonin gene-related peptide is a potent vasodilator. *Nature* **313**:54-56, 1985
126. Brain SD et al: Potent vasodilator activity of calcitonin gene-related peptide in human skin. *J Invest Dermatol* **87**:533-536, 1986
127. Brain SD, Williams TJ: Interactions between the tachykinins and calcitonin gene-related peptide lead to the modulation of oedema formation and blood flow in rat skin. *Br J Pharmacol* **97**:77-82, 1989
128. Ozaka T et al: Weibel-Palade bodies as a storage site of calcitonin gene-related peptide and endothelin-1 in blood vessels of the rat carotid body. *Anat Rec* **247**:388-394, 1997
129. Gillardon F, Morano I, Zimmermann M: Ultraviolet irradiation of the skin attenuates calcitonin gene-related peptide mRNA expression in rat dorsal root ganglion cells. *Neurosci Lett* **124**:144-147, 1991
130. Toyoda M et al: Calcitonin gene-related peptide upregulates melanogenesis and enhances melanocyte dendricity via induction of keratinocyte-derived melanotrophic factors. *J Invest Dermatol Symp Proc* **4**:116-125, 1999
131. Fischer MJ: Calcitonin gene-related peptide receptor antagonists for migraine. *Expert Opin Investig Drugs* **19**:815-823
132. Villalon CM, Olesen J: The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. *Pharmacol Ther* **124**:309-323, 2009
133. Liebow C, Lee MT, Schally A: Antitumor effects of somatostatin mediated by the stimulation of tyrosine phosphatase. *Metabolism* **39**:163-166, 1990
134. Buscail L et al: Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. *Proc Natl Acad Sci U S A* **91**:2315-2319, 1994

135. Payan DG, Hess CA, Goetzl EJ: Inhibition by somatostatin of the proliferation of T-lymphocytes and Molt-4 lymphoblasts. *Cell Immunol* **84**:433-438, 1984
136. Leszczynski D et al: Angiopeptin, the octapeptide analogue of somatostatin, decreases rat heart endothelial cell adhesiveness for mononuclear cells. *Regul Pept* **43**:131-140, 1993
137. Goetzl EJ et al: Endogenous somatostatin-like peptides of rat basophilic leukemia cells. *J Immunol* **135**:2707-2712, 1985
138. Church MK, el-Lati S, Caulfield JP: Neuropeptide-induced secretion from human skin mast cells. *Int Arch Allergy Appl Immunol* **94**:310-318, 1991
139. Pincelli C et al: Neuropeptides in skin from patients with atopic dermatitis: An immunohistochemical study. *Br J Dermatol* **122**:745-750, 1990
140. Johansson O: Morphological characterization of the somatostatin-immunoreactive dendritic skin cells in urticaria pigmentosa patients by computerized image analysis. *Scand J Immunol* **21**:431-439, 1985
141. Johansson O, Nordlind K: Immunohistochemical localization of somatostatin-like immunoreactivity in skin lesions from patients with urticaria pigmentosa. *Virchows Arch B Cell Pathol Incl Mol Pathol* **46**:155-164, 1984
142. ten Bokum AM et al: Somatostatin receptor subtype expression in cells of the rat immune system during adjuvant arthritis. *J Endocrinol* **161**:167-175, 1999
143. ten Bokum AM et al: Immunohistochemical localization of somatostatin receptor sst2A in human rheumatoid synovium. *J Rheumatol* **26**:532-535, 1999
144. Descamps V et al: Global improvement of systemic scleroderma under long-term administration of octreotide. *Eur J Dermatol* **9**:446-448, 1999
145. Luger TA et al: Cutaneous immunomodulation and coordination of skin stress responses by alpha-melanocyte-stimulating hormone. *Ann N Y Acad Sci* **840**:381-394, 1998
146. Ito N et al: Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal (HPA) axis and synthesize cortisol. *Faseb J* **19**(10):1332-1334, 2005
147. Kauser S et al: Regulation of human epidermal melanocyte biology by beta-endorphin. *J Invest Dermatol* **120**:1073-1080, 2003
148. Khodorova A et al: Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. *Nat Med* **9**:1055-1061, 2003
149. Ibrahim MM et al: CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. *Proc Natl Acad Sci U S A* **102**:3093-3098, 2005
150. Zouboulis CC, Bohm M: Neuroendocrine regulation of sebocytes—A pathogenetic link between stress and acne. *Exp Dermatol* **13**(Suppl. 4):31-35, 2004
151. Bigliardi PL et al: Specific stimulation of migration of human keratinocytes by mu-opiate receptor agonists. *J Recept Signal Transduct Res* **22**:191-199, 2002
152. Bigliardi-Qi M et al: Mu-opiate receptor and Beta-endorphin expression in nerve endings and keratinocytes in human skin. *Dermatology* **209**:183-189, 2004
153. Nissen JB et al: Decrease in enkephalin levels in psoriatic lesions after calcipotriol and mometasone furoate treatment. *Dermatology* **198**:11-17, 1999
154. Earl JR et al: Effect of mu, delta and kappa opioid receptor agonists on a reactive oxygen species mediated model of skin inflammation. *Skin Pharmacol* **9**:250-258, 1996
155. Nissen JB et al: Effect of intradermal injection of methionine-enkephalin on human skin. *Acta Derm Venereol* **79**:23-26, 1999
156. Morris JL: Distribution and peptide content of sympathetic axons innervating different regions of the cutaneous venous bed in the pinna of the guinea pig ear. *J Vasc Res* **32**:378-386, 1995
157. Stein C et al: Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. *Proc Natl Acad Sci U S A* **87**:5935-5939, 1990
158. Malekzad F et al: Efficacy of oral naltrexone on pruritus in atopic eczema: A double-blind, placebo-controlled study. *J Eur Acad Dermatol Venereol* **23**:948-950, 2009
159. Bigliardi PL et al: Treatment of pruritus with topically applied opiate receptor antagonist. *J Am Acad Dermatol* **56**:979-988, 2007
160. Gantz I, Fong TM: The melanocortin system. *Am J Physiol Endocrinol Metab* **284**:E468-E474, 2003
161. Mountjoy KG et al: The cloning of a family of genes that encode the melanocortin receptors. *Science* **257**:1248-1251, 1992
162. Hiramoto K et al: Increased alpha-melanocyte-stimulating hormone (alpha-MSH) levels and melanocortin receptors expression associated with pigmentation in an NC/Nga mouse model of atopic dermatitis. *Exp Dermatol* **19**:132-136, 2009

163. Krude H, Gruters A: Implications of proopiomelanocortin (POMC) mutations in humans: The POMC deficiency syndrome. *Trends Endocrinol Metab* 11:15-22, 2000
164. Chakraborty AK et al: UV light and MSH receptors. *Ann N Y Acad Sci* 885:100-116, 1999
165. Burchill SA, Thody AJ: Melanocyte-stimulating hormone and the regulation of tyrosinase activity in hair follicular melanocytes of the mouse. *J Endocrinol* 111:225-232, 1986
166. Wilms K: Benign (reactive) lymphoproliferation or malignant lymphoma? *Z Gesamte Inn Med* 46:53-58, 1991
167. Bohm M et al: Evidence for expression of melanocortin-1 receptor in human sebocytes in vitro and in situ. *J Invest Dermatol* 118:533-539, 2002
168. Brzoska T et al: Alpha-melanocyte-stimulating hormone and related tripeptides: Biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. *Endocr Rev* 29:581-602, 2008
169. Schiller M et al: Solar-simulated ultraviolet radiation-induced upregulation of the melanocortin-1 receptor, proopiomelanocortin, and alpha-melanocyte-stimulating hormone in human epidermis in vivo. *J Invest Dermatol* 122:468-476, 2004
170. Luger TA et al: New insights into the functions of alpha-MSH and related peptides in the immune system. *Ann N Y Acad Sci* 994:133-140, 2003
171. Loser K et al: The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans. *PLoS One* 5:e8958, 2010
172. Kokot A et al: alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: Melanocortin peptides as a novel treatment strategy for scleroderma? *Arthritis Rheum* 60:592-603, 2009
173. Bohm M et al: Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone. *J Biol Chem* 279:6959-6966, 2004
174. Cutuli M et al: Antimicrobial effects of alpha-MSH peptides. *J Leukoc Biol* 67:233-239, 2000
175. Bohm M et al: alpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. *J Biol Chem* 280:5795-5802, 2005
176. Hill RP et al: Alpha-melanocyte stimulating hormone cytoprotective biology in human dermal fibroblast cells. *Peptides* 26:1150-1158, 2005
177. Abdel-Malek ZA et al: alpha-MSH tripeptide analogs activate the melanocortin 1 receptor and reduce UV-induced DNA damage in human melanocytes. *Pigment Cell Melanoma Res* 22:635-644, 2009
178. Getting SJ et al: Melanocortin peptide therapy for the treatment of arthritic pathologies. *Scientific-WorldJournal* 9:1394-1414, 2009
179. Slominski A et al: Ultraviolet B stimulates production of corticotropin releasing factor (CRF) by human melanocytes. *FEBS Lett* 399:175-176, 1996
180. Coste SC et al: IL-1alpha and TNFalpha down-regulate CRH receptor-2 mRNA expression in the mouse heart. *Endocrinology* 142:3537-3545, 2001
181. Papadopoulou N et al: Corticotropin-releasing hormone receptor-1 and histidine decarboxylase expression in chronic urticaria. *J Invest Dermatol* 125:952-955, 2005
182. Zbytek B, Pfeffer LM, Slominski AT: Corticotropin-releasing hormone stimulates NF-kappaB in human epidermal keratinocytes. *J Endocrinol* 181:R1-R7, 2004
183. Slominski A et al: Differential expression of a cutaneous corticotropin-releasing hormone system. *Endocrinology* 145:941-950, 2004
184. Donelan J et al: Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. *Proc Natl Acad Sci U S A* 103:7759-7764, 2006
185. Lolis MS, Bowe WP, Shalita AR: Acne and systemic disease. *Med Clin North Am* 93:1161-1181, 2009
186. Ziegler CG et al: Corticotropin releasing hormone and its function in the skin. *Horm Metab Res* 39:106-109, 2007
187. Johnson GD, Stevenson T, Ahn K: Hydrolysis of peptide hormones by endothelin-converting enzyme-1. A comparison with neprilysin. *J Biol Chem* 274:4053-4058, 1999
188. Fahnoe DC et al: Inhibitor potencies and substrate preference for endothelin-converting enzyme-1 are dramatically affected by pH. *J Cardiovasc Pharmacol* 36:S22-S25, 2000
189. Zhu L et al: The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: In vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). *J Biol Chem* 278:22418-22423, 2003
190. Caldwell PR et al: Angiotensin-converting enzyme: Vascular endothelial localization. *Science* 191:1050-1051, 1976

191. Scholzen TE et al: Neutral Endopeptidase Terminates Substance P-Induced Inflammation in Allergic Contact Dermatitis. *J Immunol* **166**:1285-1291, 2001
192. Johnson AR et al: Neutral endopeptidase in serum samples from patients with adult respiratory distress syndrome. Comparison with angiotensin-converting enzyme. *Am Rev Respir Dis* **132**:1262-1267, 1985
193. Muns G, Vishwanatha JK, Rubinstein I: Effects of smokeless tobacco on chemically transformed hamster oral keratinocytes: Role of angiotensin I-converting enzyme. *Carcinogenesis* **15**:1325-1327, 1994
194. Olerud JE et al: Neutral endopeptidase expression and distribution in human skin and wounds. *J Invest Dermatol* **112**:873-881, 1999
195. Lu B et al: The control of microvascular permeability and blood pressure by neutral endopeptidase. *Nat Med* **3**:904-907, 1997
196. Steinhoff M et al: Role of neutral endopeptidase (NEP) and substance P in cutaneous inflammation: Increased plasma extravasation in NEP-deficient mice. *Arch Dermatol Res* **197**:27, 1999. (Abstract)
197. Okamoto A et al: Interactions between neutral endopeptidase (EC 3.4.24.11) and the substance P (NK1) receptor expressed in mammalian cells. *Biochem J* **299**:683-693, 1994
198. Muller L et al: Heterodimerization of endothelin-converting enzyme-1 isoforms regulates the subcellular distribution of this metalloprotease. *J Biol Chem* **278**:545-555, 2003
199. Muller L et al: Expression of the endothelin-converting enzyme-1 isoforms in endothelial cells. *J Cardiovasc Pharmacol* **36**:S15-S18, 2000
200. Kondepudi A, Johnson A: Cytokines increase neutral endopeptidase activity in lung fibroblasts. *Am J Respir Cell Mol Biol* **8**:43-49, 1993
201. Graf K et al: Activation of adenylate cyclase and phosphodiesterase inhibition enhance neutral endopeptidase activity in human endothelial cells. *Peptides* **16**:1273-1278, 1995
202. Borson DB: Roles of neutral endopeptidase in airways. *Am J Physiol* **260**:L212-225, 1991
203. Borson DB, Gruenert DC: Glucocorticoids induce neutral endopeptidase in transformed human tracheal epithelial cells. *Am J Physiol* **260**:L83-89, 1991
204. Steckelings UM et al: Human skin: Source of and target organ for angiotensin II. *Exp Dermatol* **13**:148-154, 2004
205. Roosterman D et al: Endothelin-converting enzyme 1 degrades neuropeptides in endosomes to control receptor recycling. *Proc Natl Acad Sci U S A* **104**:11838-11843, 2007
206. Cattaruzza F et al: Endothelin-converting enzyme 1 promotes re-sensitization of neurokinin 1 receptor-dependent neurogenic inflammation. *Br J Pharmacol* **156**:730-739, 2009
207. Cottrell GS et al: Endosomal endothelin-converting enzyme-1: A regulator of beta-arrestin-dependent ERK signaling. *J Biol Chem* **284**:22411-22425, 2009
208. Padilla BE et al: Endothelin-converting enzyme-1 regulates endosomal sorting of calcitonin receptor-like receptor and beta-arrestins. *J Cell Biol* **179**:981-997, 2007
209. Roosterman D et al: Endothelin-converting enzyme-1 degrades internalized somatostatin-14. *Endocrinology* **149**:2200-2207, 2008
210. Jutel M, Akdis M, Akdis CA: Histamine, histamine receptors and their role in immune pathology. *Clin Exp Allergy* **39**:1786-1800, 2009
211. Dawicki W et al: Mast cells, histamine, and IL-6 regulate the selective influx of dendritic cell subsets into an inflamed lymph node. *J Immunol* **184**:2116-2123, 2010
212. Cowden JM et al: The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. *J Invest Dermatol* **130**:1023-1033, 2010
213. Clapham DE: TRP channels as cellular sensors. *Nature* **426**:517-524, 2003
214. Chuang HH et al: Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P₂-mediated inhibition. *Nature* **411**:957-962, 2001
215. Hwang SW et al: Direct activation of capsaicin receptors by products of lipoxygenases: Endogenous capsaicin-like substances. *Proc Natl Acad Sci U S A* **97**:6155-6160, 2000
216. Mohapatra DP, Nau C: Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway. *J Biol Chem* **278**:50080-50090, 2003
217. Shin J et al: Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia. *Proc Natl Acad Sci U S A* **99**:10150-10155, 2002
218. Di Marzo V, Blumberg PM, Szallasi A: Endovanilloid signaling in pain. *Curr Opin Neurobiol* **12**:372-379, 2002

219. Caterina MJ, Julius D: The vanilloid receptor: A molecular gateway to the pain pathway. *Annu Rev Neurosci* **24**:487-517, 2001
220. Stander S, Luger T, Metzger D: Treatment of prurigo nodularis with topical capsaicin. *J Am Acad Dermatol* **44**:471-478, 2001
221. Twycross R et al: Itch: Scratching more than the surface. *Qjm* **96**:7-26, 2003
222. Yosipovitch G, Greaves MW, Schmelz M: Itch. *Lancet* **361**:690-694, 2003
223. Stander S, Steinhoff M: Pathophysiology of pruritus in atopic dermatitis: An overview. *Exp Dermatol* **11**:12-24, 2002
224. Senba E et al: The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers. *Neurosci Res* **50**:257-262, 2004
225. Stander S, Luger TA: Antipruritic effects of pimecrolimus and tacrolimus. *Hautarzt* **54**:413-417, 2003
226. Nagy I et al: The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology. *Eur J Pharmacol* **500**:351-369, 2004
227. Szallasi A: Small molecule vanilloid TRPV1 receptor antagonists approaching drug status: Can they live up to the expectations? *Naunyn-Schmiedeberg's Arch Pharmacol* **373**:273-286, 2006
228. Szallasi A, Blumberg PM: Vanilloid (Capsaicin) receptors and mechanisms. *Pharmacol Rev* **51**:159-212, 1999
229. Bodo E et al: Vanilloid receptor-1 (VR1) is widely expressed on various epithelial and mesenchymal cell types of human skin. *J Invest Dermatol* **123**:410-413, 2004
230. Denda M et al: Immunoreactivity of VR1 on epidermal keratinocyte of human skin. *Biochem Biophys Res Commun* **285**:1250-1252, 2001
231. Inoue K et al: Functional vanilloid receptors in cultured normal human epidermal keratinocytes. *Biochem Biophys Res Commun* **291**:124-129, 2002
232. Bodo E et al: A hot new twist to hair biology: Involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. *Am J Pathol* **166**:985-998, 2005
233. Southall MD et al: Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes. *J Pharmacol Exp Ther* **304**:217-222, 2003
234. Pecze L et al: Human keratinocytes are vanilloid resistant. *PLoS ONE* **3**:e3419, 2008
235. Nilius B et al: Transient receptor potential cation channels in disease. *Physiol Rev* **87**:165-217, 2007
236. Yoshioka T et al: Impact of the Gly573Ser substitution in TRPV3 on the development of allergic and pruritic dermatitis in mice. *J Invest Dermatol* **129**:714-722, 2009
237. Atayan R, Shander D, Botchkareva NV: Non-neuronal expression of transient receptor potential type A1 (TRPA1) in human skin. *J Invest Dermatol* **129**:2312-2315, 2009
238. Pozsgai G et al: Evidence for the pathophysiological relevance of TRPA1 receptors in the cardiovascular system in vivo. *Cardiovasc Res* **87**:760-768, 2010
239. Axelsson HE et al: Transient receptor potential vanilloid 1, vanilloid 2 and melastatin 8 immunoreactive nerve fibers in human skin from individuals with and without Norrbottnian congenital insensitivity to pain. *Neuroscience* **162**:1322-1332, 2009
240. Rhee MH et al: Cannabinoid derivatives: Binding to cannabinoid receptors and inhibition of adenylyl cyclase. *J Med Chem* **40**:3228-3233, 1997
241. Mackie K: Cannabinoid receptors as therapeutic targets. *Annu Rev Pharmacol Toxicol* **46**:101-122, 2006
242. Coutaux A et al: Hyperalgesia and allodynia: Peripheral mechanisms. *Joint Bone Spine* **72**:359-371, 2005
243. Howlett AC et al: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol Rev* **54**:161-202, 2002
244. Sugiura T et al: Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. *Prostaglandins Leukot Essent Fatty Acids* **66**:173-192, 2002
245. Devane WA et al: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* **258**:1946-1949, 1992
246. Klein TW, Newton C, Friedman H: Cannabinoid receptors and immunity. *Immunol Today* **19**:373-381, 1998
247. Berdyshev EV: Cannabinoid receptors and the regulation of immune response. *Chem Phys Lipids* **108**:169-190, 2000
248. Klein TW et al: The cannabinoid system and cytokine network. *Proc Soc Exp Biol Med* **225**:1-8, 2000

249. Newton CA, Klein TW, Friedman H: Secondary immunity to *Legionella pneumophila* and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. *Infect Immun* **62**:4015-4020, 1994
250. Zhu LX et al: Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. *J Immunol* **165**:373-380, 2000
251. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. *Nature* **365**:61-65, 1993
252. McAllister SD, Glass M: CB(1) and CB(2) receptor-mediated signalling: A focus on endocannabinoids. *Prostaglandins Leukot Essent Fatty Acids* **66**:161-171, 2002
253. Klein TW et al: The cannabinoid system and immune modulation. *J Leukoc Biol* **74**:486-496, 2003
254. Oka S et al: 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. *J Leukoc Biol* **76**:1002-1009, 2004
255. Rayman N et al: Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status. *J Immunol* **172**:2111-2117, 2004
256. Maestroni GJ: The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. *Faseb J* **18**:1914-1916, 2004
257. Jonsson KO, Persson E, Fowler CJ: The cannabinoid CB2 receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but not the release of beta-hexosaminidase from skin slices in vitro. *Life Sci* **78**:598-606, 2006
258. Stander S et al: Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. *J Dermatol Sci* **38**:177-188, 2005
259. Maccarrone M et al: The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. *J Biol Chem* **278**:33896-33903, 2003
260. De Petrocellis L et al: Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. *Br J Pharmacol* **143**:251-256, 2004
261. Dvorak M et al: Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. *Inflamm Res* **52**:238-245, 2003
262. Richardson JD, Kilo S, Hargreaves KM: Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. *Pain* **75**:111-119, 1998
263. Rukwied R et al: Cannabinoid agonists attenuate capsaicin-induced responses in human skin. *Pain* **102**:283-288, 2003
264. Biro T et al: The endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities. *Trends Pharmacol Sci* **30**:411-420, 2009
265. Kupczyk P, Reich A, Szepietowski JC: Cannabinoid system in the skin—A possible target for future therapies in dermatology. *Exp Dermatol* **18**:669-679, 2009
266. Burrell HE et al: Potentiation of ATP- and bradykinin-induced $[Ca^{2+}]_i$ responses by PTHrP peptides in the HaCaT cell line. *J Invest Dermatol* **128**:1107-1115, 2008
267. Inoue K, Hosoi J, Denda M: Extracellular ATP has stimulatory effects on the expression and release of IL-6 via purinergic receptors in normal human epidermal keratinocytes. *J Invest Dermatol* **127**:362-371, 2007
268. Ohara H et al: Gene expression profiling defines the role of ATP-exposed keratinocytes in skin inflammation. *J Dermatol Sci* **58**:143-151
269. Zhang N, Oppenheim JJ: Crosstalk between chemokines and neuronal receptors bridges immune and nervous systems. *J Leukoc Biol* **78**:1210-1214, 2005
270. White FA et al: Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. *Proc Natl Acad Sci U S A* **102**:14092-14097, 2005
271. LINDIA JA et al: Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. *J Pain* **6**:434-438, 2005
272. Feferman T et al: Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. *J Immunol* **174**:5324-5331, 2005
273. Verge GM et al: Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. *Eur J Neurosci* **20**:1150-1160, 2004

274. Kotani N et al: Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia. *Am J Med* **116**:318-324, 2004
275. Sonkoly E et al: IL-31: A new link between T cells and pruritus in atopic skin inflammation. *J Allergy Clin Immunol* **117**:411-417, 2006
276. Bilborough J et al: IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. *J Allergy Clin Immunol* **117**:418-425, 2006
277. Grimstad O et al: Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: A model of atopic dermatitis. *Exp Dermatol* **18**:35-43, 2009
278. Takaoka A et al: Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. *Eur J Pharmacol* **516**:180-181, 2005
279. Takaoka A et al: Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. *Exp Dermatol* **15**:161-167, 2006
280. Ip WK et al: Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: Implications for the allergic response. *Immunology* **122**:532-541, 2007
281. Le Saux S et al: Molecular dissection of human interleukin-31-mediated signal transduction through site-directed mutagenesis. *J Biol Chem* **285**:3470-3477
282. Yagi Y et al: Interleukin-31 stimulates production of inflammatory mediators from human colonic subepithelial myofibroblasts. *Int J Mol Med* **19**:941-946, 2007
283. Lin MW et al: Novel IL31RA gene mutation and ancestral OSMR mutant allele in familial primary cutaneous amyloidosis. *Eur J Hum Genet* **18**:26-32
284. Venereau E et al: Definition and characterization of an inhibitor for interleukin-31. *J Biol Chem* **285**:14955-14963
285. Church MK et al: Interaction of neuropeptides with human mast cells. *Int Arch Allergy Appl Immunol* **88**:70-78, 1989
286. Bernstein JE et al: Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. *J Am Acad Dermatol* **15**:504-507, 1986
287. Farber EM et al: Stress, symmetry, and psoriasis: Possible role of neuropeptides. *J Am Acad Dermatol* **14**:305-311, 1986
288. Naukkarinen A et al: Quantitative histochemical analysis of mast cells and sensory nerves in psoriatic skin. *J Pathol* **180**:200-205, 1996
289. Naukkarinen A, Nickoloff BJ, Farber EM: Quantification of cutaneous sensory nerves and their substance P content in psoriasis [see comments]. *J Invest Dermatol* **92**:126-129, 1989
290. Bull HA et al: Expression of nerve growth factor receptors in cutaneous inflammation [see comments]. *Br J Dermatol* **139**:776-783, 1998
291. Toyoda M, Morohashi M: Morphological assessment of the effects of cyclosporin A on mast cell-nerve relationship in atopic dermatitis. *Acta Derm Venereol* **78**:321-325, 1998
292. Sugiura H et al: Density and fine structure of peripheral nerves in various skin lesions of atopic dermatitis. *Arch Dermatol Res* **289**:125-131, 1997
293. Urashima R, Mihara M: Cutaneous nerves in atopic dermatitis. A histological, immunohistochemical and electron microscopic study. *Virchows Arch* **432**:363-370, 1998
294. Ostlere LS, Cowen T, Rustin MH: Neuropeptides in the skin of patients with atopic dermatitis. *Clin Exp Dermatol* **20**:462-467, 1995
295. Glinski W et al: Increased concentration of beta-endorphin in sera of patients with psoriasis and other inflammatory dermatoses. *Br J Dermatol* **131**:260-264, 1994
296. Katsuno M et al: Neuropeptides concentrations in the skin of a murine (NC/Nga mice) model of atopic dermatitis. *J Dermatol Sci* **33**:55-65, 2003
297. Jarvikallio A, Harvima IT, Naukkarinen A: Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. *Arch Dermatol Res* **295**:2-7, 2003
298. Heyer G et al: Histamine and cutaneous nociception: Histamine-induced responses in patients with atopic eczema, psoriasis and urticaria. *Acta Derm Venereol* **78**:123-126, 1998
299. Heyer GR, Hornstein OP: Recent studies of cutaneous nociception in atopic and non-atopic subjects. *J Dermatol* **26**:77-86, 1999
300. Steinhoff M et al: Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. *Nat Med* **6**:151-158, 2000
301. Steinhoff M et al: Proteinase-activated receptor-2 mediates itch: A novel pathway for pruritus in human skin. *J Neurosci* **23**:6176-6180, 2003

302. Shpacovitch VM et al: Agonists of proteinase-activated receptor 2 induce cytokine release and activation of nuclear transcription factor kappaB in human dermal microvascular endothelial cells. *J Invest Dermatol* **118**:380-385, 2002
303. Buddenkotte J et al: Agonists of proteinase-activated receptor-2 stimulate upregulation of intercellular cell adhesion molecule-1 in primary human keratinocytes via activation of NF-kappa B. *J Invest Dermatol* **124**:38-45, 2005
304. Rupperecht M et al: Physical stress-induced secretion of adrenal and pituitary hormones in patients with atopic eczema compared with normal controls. *Exp Clin Endocrinol Diabetes* **105**:39-45, 1997
305. Rupperecht M et al: Cortisol, corticotropin, and beta-endorphin responses to corticotropin-releasing hormone in patients with atopic eczema. *Psychoneuroendocrinology* **20**:543-551, 1995
306. Raap U, Kapp A: Neuroimmunological findings in allergic skin diseases. *Curr Opin Allergy Clin Immunol* **5**:419-424, 2005
307. Stankovic N, Johansson O, Hildebrand C: Increased occurrence of PGP 9.5-immunoreactive epidermal Langerhans cells in rat plantar skin after sciatic nerve injury. *Cell Tissue Res* **298**:255-260, 1999
308. Hsieh ST et al: Epidermal denervation and its effects on keratinocytes and Langerhans cells. *J Neurocytol* **25**:513-524, 1996
309. Ding W, Wagner JA, Granstein RD: CGRP, PACAP, and VIP modulate Langerhans cell function by inhibiting NF-kappaB activation. *J Invest Dermatol* **127**:2357-2367, 2007
310. Kodali S et al: Pituitary adenylate cyclase-activating polypeptide inhibits cutaneous immune function. *Eur J Immunol* **33**:3070-3079, 2003
311. Gillardon F et al: Regulation of calcitonin gene-related peptide mRNA expression in the hearts of spontaneously hypertensive rats by testosterone. *Neurosci Lett* **125**:77-80, 1991
312. Asahina A et al: Inhibition of the induction of delayed-type and contact hypersensitivity by calcitonin gene-related peptide. *J Immunol* **154**:3056-3061, 1995
313. Torii H et al: Regulation of cytokine expression in macrophages and the Langerhans cell-like line XS52 by calcitonin gene-related peptide. *J Leukoc Biol* **61**:216-223, 1997
314. Grabbe S et al: alpha-Melanocyte-stimulating hormone induces hapten-specific tolerance in mice. *J Immunol* **156**:473-478, 1996
315. Hartmeyer M et al: Human dermal microvascular endothelial cells express the melanocortin receptor type 1 and produce increased levels of IL-8 upon stimulation with alpha-melanocyte-stimulating hormone. *J Immunol* **159**:1930-1937, 1997
316. Brzoska T et al: Molecular basis of the alpha-MSH/IL-1 antagonism. *Ann N Y Acad Sci* **885**:230-238, 1999
317. Tanaka T et al: Effects of substance P and substance K on the growth of cultured keratinocytes. *J Invest Dermatol* **90**:399-401, 1988
318. Ziche M et al: NK1-receptors mediate the proliferative response of human fibroblasts to tachykinins. *Br J Pharmacol* **100**:11-14, 1990
319. Lusthaus S et al: Traumatic section of the median nerve: An unusual complication of Colles' fracture. *Injury* **24**:339-340, 1993
320. Ansel JC et al: Interactions of the skin and nervous system. *J Invest Dermatol Symp Proc* **2**:23-26, 1997
321. Aoki M, Tamai K, Saotome K: Substance P- and calcitonin gene-related peptide-immunofluorescent nerves in the repair of experimental bone defects. *Int Orthop* **18**:317-324, 1994
322. Aldskogius H, Hermanson A, Jonsson CE: Reinnervation of experimental superficial wounds in rats. *Plast Reconstr Surg* **79**:595-599, 1987
323. Kishimoto S: The regeneration of substance P-containing nerve fibers in the process of burn wound healing in the guinea pig skin. *J Invest Dermatol* **83**:219-223, 1984
324. Rusanen M et al: Evolution of substance P immunofluorescent nerves in callus tissue during fracture healing. *J Trauma* **27**:1340-1343, 1987
325. Wollina U et al: Vasoactive intestinal peptide and epidermal growth factor: Co-mitogens or inhibitors of keratinocyte proliferation in vitro? *Int J Mol Med* **2**:725-730, 1998
326. Wollina U et al: Vasoactive intestinal peptide supports induced migration of human keratinocytes and their colonization of an artificial polyurethane matrix. *Regul Pept* **70**:29-36, 1997
327. Haegerstrand A et al: Vasoactive intestinal polypeptide stimulates cell proliferation and adenylate cyclase activity of cultured human keratinocytes. *Proc Natl Acad Sci U S A* **86**:5993-5996, 1989
328. Haegerstrand A, Dalsgaard et al: Calcitonin gene-related peptide stimulates proliferation of human endothelial cells. *Proc Natl Acad Sci U S A* **87**:3299-3303, 1990

329. Wollina U: Vasoactive intestinal peptide supports spontaneous and induced migration of human keratinocytes and the colonization of an artificial polyurethane matrix. *Ann N Y Acad Sci* **865**:551-555, 1998
330. Watson S, Burnside T, Carver W: Angiotensin II-stimulated collagen gel contraction by heart fibroblasts: Role of the AT1 receptor and tyrosine kinase activity. *J Cell Physiol* **177**:224-231, 1998
331. Micera A et al: Nerve growth factor displays stimulatory effects on human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue repair. *Proc Natl Acad Sci U S A* **98**:6162-6167, 2001
332. Matsuda H et al: Role of nerve growth factor in cutaneous wound healing: Accelerating effects in normal and healing-impaired diabetic mice. *J Exp Med* **187**:297-306, 1998
333. Kawamoto K, Matsuda H: Nerve growth factor and wound healing. *Prog Brain Res* **146**:369-384, 2004
334. Muangman P et al: Nerve growth factor accelerates wound healing in diabetic mice. *Wound Repair Regen* **12**:44-52, 2004
335. Blomme EA et al: Parathyroid hormone-related protein is a positive regulator of keratinocyte growth factor expression by normal dermal fibroblasts. *Mol Cell Endocrinol* **152**:189-197, 1999
336. Blomme EA et al: Spatial and temporal expression of parathyroid hormone-related protein during wound healing. *J Invest Dermatol* **112**:788-795, 1999
337. Olerud JE et al: Protein gene product 9.5 is expressed by fibroblasts in human cutaneous wounds. *J Invest Dermatol* **111**:565-572, 1998
338. Lee KF et al: Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. *Cell* **69**:737-749, 1992
339. Ikoma A et al: The neurobiology of itch. *Nat Rev Neurosci* **7**:535-547, 2006
340. Dillon SR et al: Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. *Nat Immunol* **5**:752-760, 2004
341. Homey B et al: Cytokines and chemokines orchestrate atopic skin inflammation. *J Allergy Clin Immunol* **118**:178-189, 2006
342. Jones EA, Bergasa NV: The pruritus of cholestasis and the opioid system [clinical conference]. *Jama* **268**:3359-3362, 1992
343. Jones EA, Bergasa NV: The pruritus of cholestasis [In Process Citation]. *Hepatology* **29**:1003-1006, 1999
344. Johansson O et al: A serotonin-like immunoreactivity is present in human cutaneous melanocytes. *J Invest Dermatol* **111**:1010-1014, 1998
345. Klein TW: Cannabinoid-based drugs as anti-inflammatory therapeutics. *Nat Rev Immunol* **5**:400-411, 2005
346. Singh ME, McGregor IS, Mallet PE: Repeated exposure to Delta(9)-tetrahydrocannabinol alters heroin-induced locomotor sensitisation and Fos-immunoreactivity. *Neuropharmacology* **49**:1189-1200, 2005
347. Akerman S, Kaube H, Goadsby PJ: Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. *Br J Pharmacol* **142**:1354-1360, 2004
348. van der Stelt M et al: Anandamide acts as an intracellular messenger amplifying Ca²⁺ influx via TRPV1 channels. *Embo J* **24**:3026-3037, 2005
349. Ikoma et al: Anatomy and neurophysiology of pruritus. *Semin Cutan Med Surg* **30**:64-70, 2011

